# US 2019/0375789 A1 · Immune system modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375789 A1
- Document ID: US20190375789A1
- Status: Published application
- Kind: A1
- Application number: 16/379,654
- Filed: 2019-04-09
- Published: 2019-12-12
- Earliest claimed: 2013-09-09
- Assignees: Canimguide Therapeutics AB
- Applicants: Canimguide Therapeutics AB
- Inventors: Leif Håkansson
- Web page: https://patentgrep.com/patent/US20190375789A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/70546: {Integrin superfamily}
- C07K 14/7155: {for interleukins [IL]}
- C07K 14/76: Albumins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention described herein relates to compositions that interact with molecules that suppress the immune system. More specifically, embodiments described herein concern the discovery, manufacture, and use of compositions that remove immunosuppression the immune system by binding to immunoregulatory peptides that interact with receptors on immune cells, compositions the can stimulate immune cells, and compositions that are cytotoxic to tumor cells.

## Claims

### Claim at position 1

-88. (canceled)

### Claim 89

A method of binding a cancer cell or an immune cell with an isolated peptide the method comprising:
contacting the cancer cell or the immune cell with the isolated peptide, the isolated peptide comprising the amino acid sequence FFVKLS (SEQ ID NO: 62), wherein the isolated peptide comprises no more than 30 amino acid residues; and
detecting the binding of said isolated peptide to said cancer cell or immune cell.

### Claim 90 (depends on 89)

The method of claim 89, wherein the isolated peptide comprises a detectable moiety.

### Claim 91 (depends on 90)

The method of claim 90, wherein the detectable moiety comprises a biotinylated label, a radioactive label, a fluorescent label, an enzyme, or a colloidal gold label.

### Claim 92 (depends on 89)

The method of claim 89, wherein the cancer cell is a colorectal cancer cell, a renal cancer cell, a breast cancer cell, a skin cancer cell, an ovarian cancer cell, a prostate cancer cell, a pancreatic cancer cell, a lung cancer cell, a malignant melanoma cell, a small cell lung cancer cell, a non-small lung cancer (adenocarcinoma) cell, a squamous cell carcinoma cell, a bladder cancer cell, an osteosarcoma cell, a bronchial cancer cell, or a hematopoietic cell cancer cell.

### Claim 93 (depends on 89)

The method of claim 89, wherein the immune cell is selected from the group consisting of a leukocyte, a PBMC, a lymphocytes, a monocyte, and a macrophage.

### Claim 94 (depends on 89)

The method of claim 89, wherein the immune cell is selected from the group consisting of an immunosuppressor cell, a regulatory T-cell, an immature dendritic cell, a tumor associated macrophage, and a myeloid-derived suppressor cell.

### Claim 95 (depends on 89)

The method of claim 89, wherein the isolated peptide binds to at least one of: an aggregate of albumin, a denatured albumin, a damaged albumin, or a peptide comprising the amino acid sequence of SEQ ID NO: 185.

### Claim 96 (depends on 89)

The method of claim 89, wherein said peptide comprises an antibody fragment.

### Claim 97 (depends on 89)

The method of claim 89, further comprising binding an antibody or fragment thereof to the peptide to detect the presence of the peptide.

### Claim 98 (depends on 89)

The method of claim 89, wherein the isolated peptide comprises no more than 29 amino acid residues.

### Claim 99 (depends on 89)

The method of claim 89, wherein the isolated peptide comprises no more than 16 amino acid residues.

### Claim 100 (depends on 89)

The method of claim 89, wherein the isolated peptide comprises no more than 8 amino acid residues.

### Claim 101 (depends on 89)

The method of claim 89, wherein the isolated peptide consists of the amino acid sequence FFVKLS (SEQ ID NO: 62).

### Claim 102 (depends on 89)

The method of claim 89, wherein the isolated peptide comprises the amino acid sequence KKLDTFFVKLSLFTER (SEQ ID NO: 2).

### Claim 103 (depends on 89)

The method of claim 89, wherein the isolated peptide consists of the amino acid sequence KKLDTFFVKLSLFTER (SEQ ID NO: 2).

### Claim 104 (depends on 89)

The method of claim 89, wherein the isolated peptide comprises the amino acid sequence RKLDTFFVKLSLFTERRR (SEQ ID NO: 586).

### Claim 105 (depends on 89)

The method of claim 89, wherein the isolated peptide consists of the amino acid sequence RKLDTFFVKLSLFTERRR (SEQ ID NO: 586).
